Search Results - application+%3e+therapeutics

791 Results Sort By:
Gene Therapy for Leber Congenital Amaurosis
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations. This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Innovative Gene Therapy for Retinal Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases. This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Susan Gentleman, Thomas Redmond
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Virus/Bacteria, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Advanced Gene Editing Technology for Therapeutic Applications
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications. This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited,...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Ruchi Sharma, Kapil Bharti
Keywords(s):  
Category(s): Application > Therapeutics, Application > Research Materials, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases. This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1),...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Paul Sieving, Alaknanda MIshra, Vijayasarathy Camasamudram, Lisa Wei
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Immunosuppressive Exosomes for Treating Autoimmune Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases. This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Minkyung Kang, Charles Egwuagu
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Carriers/Adjuvants, TherapeuticArea > Immunology, TherapeuticArea > Neurology, TherapeuticArea > Ophthalmology
Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma. This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Myungkuk Joe
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology
A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery. This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE)...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Kapil Bharti, Fnu Ruchi, Davide Ortolan
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human iPSC Lines, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology, TherapeuticArea > Geriatrics
Biodegradable Tissue Scaffold for Multi-Tissue Transplantation
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation. This technology includes a dual-layer biodegradable tissue scaffold designed for the transplantation of multiple tissue types, such as retinal pigment epithelium (RPE)...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Arvydas Maminishkis, Kapil Bharti, Davide Ortolan, Ruchi Sharma
Keywords(s):  
Category(s): Application > Medical Devices, Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Ophthalmology
RPGR Gene Therapy for Retinitis Pigmentosa
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa. This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Michael Sandberg, Basil Pawlyk, Xinhua Shu, Robin Ali, Alan Wright, Tiansen Li
Keywords(s):  
Category(s): Application > Therapeutics, Application > Research Materials, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, ResearchProducts > Virus/Bacteria, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Targeted Disruption of Rpe65 Gene for Retinal Disease Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies. This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for...
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s): Thomas Redmond, Karl Pfeifer
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
1 2 3 4 5 6 7 8 9 10 ...